Oxford Nanopore Technologies plc (ONTTF)
OTCMKTS · Delayed Price · Currency is USD
2.846
+0.006 (0.21%)
Aug 22, 2025, 4:00 PM EDT
ONTTF Revenue
In the year 2024, Oxford Nanopore Technologies had annual revenue of 183.19M GBP with 7.97% growth. Oxford Nanopore Technologies had revenue of 99.11M in the half year ending December 31, 2024, with 29.97% growth.
Revenue
183.19M GBP
Revenue Growth
+7.97%
P/S Ratio
11.83
Revenue / Employee
132.55K GBP
Employees
1,382
Market Cap
2.71B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 183.19M | 13.52M | 7.97% |
| Dec 31, 2023 | 169.67M | -28.94M | -14.57% |
| Dec 31, 2022 | 198.60M | 64.94M | 48.59% |
| Dec 31, 2021 | 133.66M | 19.80M | 17.39% |
| Dec 31, 2020 | 113.86M | 61.80M | 118.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.09M |
| Silence Therapeutics | 27.17M |
| Global Cord Blood | 196.10M |
Oxford Nanopore Technologies News
- 18 days ago - ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology - Business Wire
- 5 weeks ago - FTSE 100 Breaks 9,000 as Miners Surge - Investomania
- 4 months ago - Breakthrough algorithm enables partially phased, near telomere-to-telomere assembly using standard Oxford Nanopore Simplex reads - Business Wire
- 4 months ago - Oxford Nanopore Expands Compatible Products Programme and Strengthens Multi-Omics Ecosystem - Business Wire
- 6 months ago - Oxford Nanopore Technologies plc (ONTTF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 months ago - UK Stock Market News: Greggs, Beazley, Oxford Nanopore - The Armchair Trader
- 8 months ago - UK Stock Market News: PageGroup, Oxford Nanopore, Entain - The Armchair Trader
- 9 months ago - Oxford Nanopore and UK Biobank to create world's first epigenetic dataset targeting the causes of cancer, dementia, complex disease - Business Wire